Evaluation of a quality assurance program for quantitation of human immunodeficiency virus type 1 RNA in plasma by the AIDS Clinical Trials Group virology laboratories
about
Comparison of two human immunodeficiency virus (HIV) RNA surrogate assays to the standard HIV RNA assayExternal quality assessment program for qualitative and quantitative detection of hepatitis C virus RNA in diagnostic virology.Multilaboratory Comparison of Hepatitis C Virus Viral Load AssaysIntra- and interlaboratory variabilities of results obtained with the Quantiplex human immunodeficiency virus type 1 RNA bDNA assay, version 3.0Magnetic silica extraction for low-viremia human immunodeficiency virus type 1 genotypingIntra-assay performance characteristics of five assays for quantification of human immunodeficiency virus type 1 RNA in plasmaDeterminations of levels of human immunodeficiency virus type 1 RNA in plasma: reassessment of parameters affecting assay outcome. TUBE Meeting Workshop Attendees. Technology Utilization for HIV-1 Blood Evaluation and Standardization in Pediatrics.Ultrasensitive reverse transcription-PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasmaRatio of two successive optical densities from the Roche HIV-1 monitor test as a measure of accuracy of estimates of human immunodeficiency virus RNA concentrationEffects of anticoagulant, processing delay, and assay method (branched DNA versus reverse transcriptase PCR) on measurement of human immunodeficiency virus type 1 RNA levels in plasmaMulticenter evaluation of methods to quantitate human immunodeficiency virus type 1 RNA in seminal plasmaComparison of two amplification technologies for detection and quantitation of human immunodeficiency virus type 1 RNA in the female genital tract. Division of AIDS Treatment Research Initiative 009 Study Team.Performance characteristics of the QUANTIPLEX HIV-1 RNA 3.0 assay for detection and quantitation of human immunodeficiency virus type 1 RNA in plasma.Evaluation of the abbott LCx HIV-1 RNA quantitative, a new assay for quantitative determination of human immunodeficiency virus type 1 RNA.Quality of human immunodeficiency virus viral load testing in Australia.Effect of errors in the sequence of optical densities from the Roche AMPLICOR HIV-1 MONITOR assay on the validity of assay results.Multisite comparison of reproducibility and recovery from the standard and ultrasensitive Roche AMPLICOR HIV-1 MONITOR assaysQuantitation of human immunodeficiency virus type 1 RNA in plasma by using blood dried on filter paper.Absolute copy number and relative change in determinations of human immunodeficiency virus type 1 RNA in plasma: effect of an external standard on kit comparisons.HIV dynamics in seminal plasma during primary HIV infectionCross-platform analysis of HIV-1 RNA data generated by a multicenter assay validation study with wide geographic representation.T-cell activation, both pre- and post-HAART levels, correlates with carotid artery stiffness over 6.5 years among HIV-infected women in the WIHSIn vitro preclinical testing of nonoxynol-9 as potential anti-human immunodeficiency virus microbicide: a retrospective analysis of results from five laboratories.Comparison of the sensitivities of the version 1.5 and version 1.0 ultrasensitive Roche AMPLICOR HIV-1 MONITOR kits at low concentrations of human immunodeficiency virus RNAMonitoring the quality of HIV-1 viral load testing through a proficiency testing program using dried tube specimens in resource-limited settings.Early initiation of lopinavir/ritonavir in infants less than 6 weeks of age: pharmacokinetics and 24-week safety and efficacy.Baseline resistance to nucleoside reverse transcriptase inhibitors fails to predict virologic response to combination therapy in children (PACTG 338).Associations between virologic and immunologic dynamics in blood and in the male genital tract.Comparison of Three Different FDA-Approved Plasma HIV-1 RNA Assay Platforms Confirms the Virologic Failure Endpoint of 200 Copies per Milliliter Despite Improved Assay Sensitivity.Assessment of lopinavir pharmacokinetics with respect to developmental changes in infants and the impact on weight band-based dosing.Interpreting quantitative cytomegalovirus DNA testing: understanding the laboratory perspectiveRing test evaluation of the detection of influenza A virus in swine oral fluids by real-time reverse-transcription polymerase chain reaction and virus isolationMulticenter comparison of three commercial methods for quantification of human immunodeficiency virus type 1 RNA in plasma.Comparison of the Amplicor HIV-1 monitor test and the nucleic acid sequence-based amplification assay for quantitation of human immunodeficiency virus RNA in plasma, serum, and plasma subjected to freeze-thaw cycles.Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093A novel PCR assay for quantification of HIV-1 RNA.Bimodal virological response to antiretroviral therapy for HIV infection: an application using a mixture model with left censoringShedding of HIV and human herpesviruses in the semen of effectively treated HIV-1-infected men who have sex with men.Biological and technical variables affecting immunoassay recovery of cytokines from human serum and simulated vaginal fluid: a multicenter study.Herpes viruses and HIV-1 drug resistance mutations influence the virologic and immunologic milieu of the male genital tract.
P2860
Q24535105-6C89C798-E15C-4645-B0DB-84B6F8E82FFBQ27471433-1E8C8EE0-9CD1-4A3B-9DB9-9B2E94D072B3Q27473252-E50558DA-D840-4E6D-889D-03252D39FB5FQ28364015-F62D74D6-250B-4888-AA97-6AFD3E3871B9Q33264429-F238B739-EAC5-4B2A-A891-854B427AB47DQ33660617-F9FF9E31-A9E0-40B4-AD46-816FEDA0DC6DQ33668265-7F824F70-D0DD-436D-8608-119450B3F699Q33678850-1BDCC303-B5E5-45A4-B342-23014E3F1F86Q33950074-52488256-E692-442F-B3F2-0148E8B444BBQ33961871-0E12E0B4-71FC-4C74-98B8-C3B0B5755AA8Q33967524-5CC933A5-7A78-4865-90F2-64918909656AQ33968223-0B93F7A6-F9BE-4FA3-B093-C3B9E2D417D9Q33968714-B57C6EA4-2952-4172-9AED-85DFB5263EB4Q33970109-CAB611CF-A1E2-455A-A17A-2D8D9D0D79F4Q33970212-BA2210D6-4E65-4E8B-A84D-7471C08F21ECQ33971645-0A6AF0F8-B210-44E7-BA46-FEA00FBC43C7Q33971651-1A2D9578-AFA8-4149-85E3-100F294B6769Q34073402-EB543037-3652-4221-A202-8E1FB89ADF8DQ34073785-F5757536-2B3A-44A5-8B8C-AA241266E8B3Q34083267-09BEA3E2-738C-4610-961C-DBB3E3FC84C0Q34301929-6F977141-55F9-42C6-B5F9-4F5299C418B6Q34342183-8948C63A-64E1-4446-81FA-164816E2A099Q34352144-BE688B4A-C8F6-4218-9173-3291F02E1B2FQ34782631-D8713471-23D2-420A-9CD5-0BCFD5EDE376Q35193119-7A785112-C1E5-4946-AA3D-313A2553EA07Q35222977-6365C1DD-8DCA-4980-B221-DFC7A5569516Q35647376-6A19E6D5-EFD2-49EC-AB51-5B1FCC89C887Q35689689-CBFE208F-1787-4682-8787-A69CBC70CF45Q35868687-6EA648F3-C96C-4128-91BC-1C8952C475BCQ35973937-A690430E-21B9-4152-BDE6-22B6800DEA2FQ35977398-0105F22D-E8DE-4D44-BAB0-164FA9ABB0EAQ36390109-45C0E277-CF57-43C1-8336-0BC48E8443A5Q36542026-F7CD6028-F01A-4A84-A77F-8AED0DBB2A09Q36548250-5E7CED54-65D1-401C-9730-7932ED27DDD4Q36714041-85D09616-CEB3-417E-AC73-F7C4967CC22DQ36827196-556A5E78-047B-404A-A720-6DA6125E5969Q36933327-C567042F-3486-4A54-867D-19B518E5B41EQ36987593-DD245A1B-8CEC-435E-A382-B9B8C96B48D6Q37107494-DB65B7FD-0003-4CD4-8D87-B85148453D8AQ37160784-7D9D577A-F4E7-4101-8FA5-F31A6E54B248
P2860
Evaluation of a quality assurance program for quantitation of human immunodeficiency virus type 1 RNA in plasma by the AIDS Clinical Trials Group virology laboratories
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Evaluation of a quality assura ...... ls Group virology laboratories
@ast
Evaluation of a quality assura ...... ls Group virology laboratories
@en
type
label
Evaluation of a quality assura ...... ls Group virology laboratories
@ast
Evaluation of a quality assura ...... ls Group virology laboratories
@en
prefLabel
Evaluation of a quality assura ...... ls Group virology laboratories
@ast
Evaluation of a quality assura ...... ls Group virology laboratories
@en
P2093
P2860
P1476
Evaluation of a quality assura ...... ls Group virology laboratories
@en
P2093
B Yen-Lieberman
D Brambilla
D Katzenstein
P2860
P304
P407
P577
1996-11-01T00:00:00Z